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 
Abstract— Neuromodulation of peripheral nerves has long 
been viewed as a viable alternative treatment modality for 
suppressing Neurogenic Detrusor Overactivity (NDO). Research 
has continued over decades yet translation into patient use 
remains elusive. Questions have been asked as to the long term 
efficacy of continuous stimulation and a viable system using 
conditional stimulation has so far not been realised. Herein lies 
an opportunity for the research and development of a practical, 
non-invasive, neuromodulation system to treat NDO. To do so, 
further investigation of practical stimulation triggers and 
regimes is necessary. This paper presents the design of a wireless 
device for flexible delivery and assessment of stimulation 
techniques outside of the laboratory.     
I. INTRODUCTION 
 Supra-sacral spinal cord injury (SCI) causes serious 
disruption to the function of the lower urinary tract, often 
resulting in Neurogenic Detrusor Overactivity (NDO) and 
Detrusor Sphincter Dyssynergia (DSD). These two conditions 
affect the storage and voiding phases of the micturition cycle 
and can lead to both high intra-detrusor pressures and 
incontinence [1]. The impact of SCI on the bladder is keenly 
felt in the SCI population and research into this area is 
consistently cited as a priority [2].  
Urological management goals are to protect the upper 
urinary tract and maintain continence. This is achieved by 
reducing NDO. Current management techniques do this 
pharmacologically, surgically or with implanted electrical 
stimulation devices. All have associated risks and side effects 
that may render them ineffective or unfavourable. 
Neuromodulation is an alternative treatment for NDO that 
takes advantage of the still intact lumbosacral spinal pathways 
following SCI, using electrical stimulation of the Sacral or 
Pudendal nerves to suppress bladder activity and promote 
continence [3]. Transcutaneous neuromodulation techniques 
have been investigated for decades yet no system has been 
offered to SCI community [4]. 
Continuous stimulation has been shown to be effective at 
suppressing NDO in a laboratory setting but its clinical 
implementation is limited by problems of power consumption 
and the potential habituation of reflexes. Conditional 
stimulation, applied as NDO occurs, has been shown to be as 
effective [5] and may offer the advantage of reducing the 
problems mentioned above. The problem with this approach 
lies in implementing a conditional stimulation system. The 
chronic measurement of bladder activity has been a subject of 
much frustration and of ongoing research [6]. 
Other avenues have been explored to avoid the need for this 
measurement. Acute and more chronic tests of user initiated 
stimulation (UIS) and semi-conditional stimulation have 
reported favourable results [7]-[9]. These results suggest an 
effective device could be implemented that is not wholly 
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conditional and that further research into alternative 
stimulation triggers and regimes is warranted. 
This paper outlines the development of a device to aid 
research into the efficacy of neuromodulation in the 
ambulatory environment, with the capability to wirelessly 
deliver and assess a range of stimulation regimes and triggers. 
We will use this tool to design and assess practical methods of 
delivering neuromodulation to treat NDO through everyday 
life. 
II. DESIGN 
To be capable of controlling and assessing stimulation 
regimes the design consists of two main components, a 
controller for a commercially available stimulator (Odstock 
Medical stimulator (OMS)) and a app-based user interface, for 
researchers and patients to input and read information (see 
figure 2). Stimulation parameters of pulse frequency, pulse 
width, shape and amplitude are set on the commercially 
available stimulator and will be based on previous acute 
evaluation of response to neuromodulation in each user. 
The user interface, delivered through a smart device based 
app, functions in three modes (illustrated in figure 1). First for 
the researcher or clinician to input the stimulation regime and 
trigger type they wish to implement along with relevant test 
information. This is loaded from the user interface to the 
controller, to complete the stimulation algorithm. Secondly, it 
offers a patient interface to be used for stimulation on-off 
control and diary entry of relevant information. Thirdly to 
collate the diary and stimulation data captured for a post test 
review and export. This data will be time-stamped in sync with 
simultaneously recorded ambulatory urodynamic data to allow 
review of stimulation tests against objective data.  
The role of the controller is to turn the stimulation on and 
off at the correct times, to deliver the program set by the 
researcher. This controller will be constructed from a 
microcontroller, Bluetooth module, RTC, SD module and 
power supply directly connected to the OMS through a single 
cable. The core stimulation algorithm is stored and actioned 
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Figure 1. Initial designs for User Interface. From left to right - 1. Parameter 
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here, informed by specific parameters relating to stimulation 
regimes and triggers sent to the controller wirelessly from the 
user interface. This wireless communication between the 
controller and app-based user interface will be achieved using 
Bluetooth technology. The controller will be located with the 
OMS, during tests it need not be accessed by the patient. The 
user interface, with its patient diary function, should be easily 
accessible.  Fig. 2. outlines the components in the system and 
their interactions. 
 Ambulatory urodynamic data, when relevant to a study, will 
be captured concurrently using a commercially available 
device. This involves measuring detrusor pressure (Pdet) over 
the course of a study. Abdominal (Pabd) and vesicle (Pves) 
pressures are recorded from pressure transducers attached to 
urethral and rectal catheters, Pdet is then calculated as Pves-Pabd. 
Previous research [10] has concentrated on conditional 
stimulation, relying on ambulatory urodynamic measurements 
to deliver stimulation in response to an increase in pressure. 
However, indwelling pressure measurement is not a long-term 
solution. The design presented here takes a different approach, 
using detrusor pressure measurement as an objective outcome 
measure as opposed to an active component in our system. 
Patient diary inputs and stimulation times will also be recorded. 
This will enrich the ambulatory urodynamic data to lead to a 
better understanding of the effects of each tested stimulation 
mode.  
Constraints placed on the design of the controller relate to 
size, power consumption and safety. In addition, the user 
interface must address usability constraints. We have currently 
based specifications on being able to support seven day studies 
in the home environment. Users will range in mobility from 
wheelchair users with limited hand dexterity to walking users 
with full hand function. The design must accommodate all, 
throughout activities of daily living.  
III. DISCUSSION 
The main considerations in the design of this device have 
been to allow the user to maintain a true to life environment 
and to allow input flexibility whilst ensuring relevant data is 
captured. By developing a modular system, we aim to enable a 
future add-on for collection of urodynamic data within the 
same system. The option is also left open for greater use of 
software in the process, integrating the available data into one 
place may allow a more holistic view of outcomes and provide 
a basis for designing a more intelligent system.  
Use of a wireless system will allow the whole assessment 
to take place with the stimulator in place, minimising the 
burden on the user and the risk of the system dislodging during 
activities of daily living. Untethered control allows easier 
access to the on-off control for the user, particularly users with 
limited hand dexterity who may also benefit from the use of a 
touchscreen user interface. 
There are multiple regimes and triggers that may be 
suitable for effectively delivering stimulation. A key point in 
designing this device is to enable this range to be accessed and 
adapted through one common platform. This is particularly 
challenging in a population with such wide ranging 
requirements, where it is probable that individual adaptation of 
stimulation parameters and delivery techniques would be 
necessary. In this version, the device will provide a framework 
to assess semi-conditional, user initiated and timing based 
stimulation. The flexibility to modify, combine and add new 
trigger or regime paradigms will be built in. This flexibility will 
be used to develop a truly translational neuromodulation 
device, where personalised stimulation modes may be 
developed for individuals. 
The device is currently under development and a prototype 
will be presented at the conference. It is intended to be used in 
ambulatory neuromodulation trials at London Spinal Cord 
Injuries Centre (LSCIC). Should this study be successful in 
identifying a practical neuromodulation paradigm, we will 
expand our prototype's capabilities and evaluate its suitability 
for clinical use. 
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Figure 2. Block diagram of system outlining components and interactions 
relative to both patient and researcher 
